Rahul Dhanda, Syntis Bio CEO
June 11, 2024 07:25 AM EDTUpdated 07:54 AM
Financing

New obe­si­ty biotech Syn­tis Bio launch­es with ear­ly-stage al­ter­na­tive to GLP-1s

Katherine Lewin

News Reporter

Syn­tis Bio is join­ing a grow­ing group of small­er com­pa­nies that are mov­ing in­to the obe­si­ty treat­ment space — but not with a GLP-1.

In­stead, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times